Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts. Show more

80 Guest Street, Boston, MA, 02135, United States

https://www.compasstherapeutics.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

923.1M

52 Wk Range

$1.33 - $6.88

Previous Close

$5.19

Open

$5.24

Volume

1,467,011

Day Range

$5.20 - $5.52

Enterprise Value

713.1M

Cash

219.9M

Avg Qtr Burn

-10.85M

Insider Ownership

11.14%

Institutional Own.

87.65%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Tovecimig (CTX-009) (DLL4 and VEGF-A bispecific antibody) Details Biliary Tract Cancer	Phase 2/3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTX-471 +/- KEYTRUDA® (pembrolizumab) Details Cancer, Small cell lung cancer, Non-small cell lung carcinoma, Melanoma	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tovecimig (CTX-009) (DLL4 and VEGF-A bispecific antibody) Details Colorectal cancer	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTX-8371 Details Cancer, Solid tumor/s	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTX-10726 (PD-1 x VEGF-A bispecific antibody) Details Solid tumor/s	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.